LO LOESTRIN FE
LOE Approachingnorethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate
NDAORALTABLET
Approved
Oct 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
5/8 — Partial
LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate) is ovulation. First approved in 2010.
Drug data last refreshed Yesterday · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LO LOESTRIN FE is an oral contraceptive tablet combining norethindrone acetate and ethinyl estradiol with ferrous fumarate (iron supplement). It prevents pregnancy by suppressing ovulation and is designed as a low-dose hormonal contraceptive option. The iron component addresses menstrual blood loss concerns common in oral contraceptive users.
$0.001BPart D
LOE Approaching2.3 years to LOEWith LOE approaching in 2.3 years and modest Part D spending ($1M), brand team focus will shift toward lifecycle extension strategies and potential market consolidation.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.